A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

NCT05302284 PHASE3 RECRUITING

This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.

Details

Lead sponsor	RemeGen Co., Ltd.
Phase	PHASE3
Status	RECRUITING
Enrolment	452
Start date	Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Apr 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Urothelial Carcinoma
• HER2-expressing

Interventions

• RC48-ADC
• Toripalimab
• Gemcitabine
• Cisplatin
• Carboplatin

Countries

China